Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Deletion/Duplication Mutation Screening of Tp53 Gene in Patients With Transitional Cell Carcinoma of Urinary Bladder Using Multiplex Ligation-Dependent Probe Amplification Publisher Pubmed



Bazrafshani MRR1 ; Nowshadi PA2 ; Shirian S3, 4, 5 ; Daneshbod Y6 ; Nabipour F2 ; Mokhtari M7 ; Hosseini F8 ; Dehghan S9 ; Saeedzadeh A6 ; Mosayebi Z10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Genetics Department, Kerman University of Medical Sciences, Kerman, Iran
  2. 2. Department of Pathology, Kerman University of Medical Sciences, Kerman, Iran
  3. 3. Department of Pathology, School of Veterinary Pathology, Shahrekord University, Shahrekord, Iran
  4. 4. Shefa Neuroscience Research Center, Khatam-Al-Anbia Hospital, Tehran, Iran
  5. 5. Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Cytopathology, Research Center of Dr. Daneshbod Path Lab, Shiraz, Iran
  7. 7. Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
  8. 8. Department of Genetics, Dr. Mohammad-Reza Bazrafshani Lab, Kerman, Iran
  9. 9. Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  10. 10. Department of Pediatrics, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Cancer Medicine Published:2016


Abstract

Bladder cancer is a molecular disease driven by the accumulation of genetic, epigenetic, and environmental factors. The aim of this study was to detect the deletions/duplication mutations in TP53 gene exons using multiplex ligation-dependent probe amplification (MLPA) method in the patients with transitional cell carcinoma (TCC). The achieved formalin-fixed paraffin-embedded tissues from 60 patients with TCC of bladder were screened for exonal deletions or duplications of every 12 TP53 gene exons using MLPA. The pathological sections were examined by three pathologists and categorized according to the WHO scoring guideline as 18 (30%) grade I, 22 (37%) grade II, 13 (22%) grade III, and 7 (11%) grade IV cases of TCC. None mutation changes of TP53 gene were detected in 24 (40%) of the patients. Furthermore, mutation changes including, 15 (25%) deletion, 17 (28%) duplication, and 4 (7%) both deletion and duplication cases were observed among 60 samples. From 12 exons of TP53 gene, exon 1 was more subjected to exonal deletion. Deletion of exon 1 of TP53 gene has occurred in 11 (35.4%) patients with TCC. In general, most mutations of TP53, either deletion or duplication, were found in exon 1, which was statistically significant. In addition, no relation between the TCC tumor grade and any type of mutation were observed in this research. MLPA is a simple and efficient method to analyze genomic deletions and duplications of all 12 exons of TP53 gene. The finding of this report that most of the mutations of TP53 occur in exon 1 is in contrast to that of the other reports suggesting that exons 5-8 are the most (frequently) mutated exons of TP53 gene. The mutations of exon 1 of TP53 gene may play an important role in the tumorogenesis of TCC. © 2016 Published by John Wiley & Sons Ltd.
Related Docs
1. High Resolution Melting Analysis for Rapid Detection of Pik3ca Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy, Urology Journal (2018)
2. High Resolution Melting Analysis for Rapid Detection of Pik3ca Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy, Urology Journal (2018)
Experts (# of related papers)
Mohammad Reza Pourmand (2)